{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"106.9","value":"162"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.2","value":"794"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"The observed maximum plasma concentration following administration","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Ceritinib administered continuously through oral dosing at a dosage of 750 mg once daily in fasted state","id":"OG000","title":"Ceritinib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The Pharmacokinetic Analysis Set (PAS) consisted of all patients who received at least one (full or partial) dose of LDK378 and provided at least one evaluable pharmacokinetic (PK) blood sample. Only the subset of participants with extensive PK collection were analyzed.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 and Cycle 2 Day 1 at pre-dose, 1, 2, 4, 6, 8 and 24 hours post-dose. Cycle=21 days","title":"Cmax of LDK378","type":"SECONDARY","unitOfMeasure":"nanogram (ng) / mililiter (ml)"}